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Genetic alterations that promote chromosome missegregation have been proposed to drive tumorigenesis
through loss of whole chromosomes containing key tumor suppressor genes. To test this unproven idea,
we bred Bub1 mutant mice that inaccurately segregate their chromosomes onto p53+/–, ApcMin/+, Rb+/–, or
Pten+/– backgrounds. Bub1 insufficiency predisposed p53+/– mice to thymic lymphomas and ApcMin/+
mice to colonic tumors. These tumors consistently lacked the nonmutated tumor suppressor allele but
had gained a copy of the mutant allele. In contrast, Bub1 insufficiency had no impact on tumorigenesis in
Rb+/– mice and inhibited prostatic intraepithelial neoplasia formation in Pten+/– mice. Thus, Bub1 insuffi-
ciency can drive tumor formation through tumor suppressor gene loss of heterozygosity, but only in
restricted genetic and cellular contexts.INTRODUCTION
Aneuploidy, an abnormal number of chromosomes, is a distinc-
tive feature of most human cancers; however, its role in
neoplastic transformation is somewhat mysterious (Ricke et al.,
2008). On the one hand, there is ample evidence that chromo-
some imbalances reduce cell proliferation and overall organ-
ismal fitness (Torres et al., 2008), arguing against a causal role
for aneuploidy in malignant cell growth. On the other hand,
some of the mousemodels for aneuploidy that have been gener-
ated are prone to late-life tumors (Iwanaga et al., 2007; Jegana-
than et al., 2007; Michel et al., 2001; Sotillo et al., 2007; Weaver
et al., 2007), suggesting that aneuploidy has the ability to
contribute to tumorigenesis. Although studies of chromosomal
instability in mice have provided some evidence for a causal
link between aneuploidy and cancer, they also raised several
key questions (Ricke et al., 2008). For instance, why do chromo-Csomal instability genes that are active in a wide variety of tissues
throughout the body promote tumorigenesis only in a few tissues
when defective, and why do tumor prone tissues vary between
different aneuploidy models? Also, why are some of the models
not prone to tumors despite the presence of vast amounts of
aneuploid cells, and why do some chromosomal instability
gene defects exert tumor suppressive ability in certain genetic
contexts? Clearly, the totality of currently available data suggest
that the mechanisms by which whole chromosome instability
gene defects affect tumor development are highly complex
and depend on the particular gene that is defective and the
severity of the defect.
One mechanism through which chromosomal instability is
thought to promote tumorigenesis is by increasing loss of tumor
suppressor genes (Michor et al., 2005). The central idea is that, in
instances where one copy of a particular tumor suppressor gene
has suffered a mutation, the chromosome harboring the second,SIGNIFICANCE
Aneuploidy is a hallmark of human cancers, but the central question as to whether chromosomal instability gene mutations
contribute to cancer by eliminating tumor suppressor genes through loss of whole chromosomes remains unresolved. By
crossing Bub1 mutant mice with high rates of chromosome missegregation onto heterozygous null backgrounds for various
prominent tumor-suppressor genes, we provide evidence that cancer can be caused by a mechanism of tumor suppressor
gene inactivation that involves whole chromosome loss. Remarkably, cells that lose the chromosome that contains the wild-
type tumor suppressor gene copy, consistently gain an extra copy of the chromosome harboring the inactive allele, implying
a strong selective pressure for tumor suppressor gene loss of heterozygosity without losing the other genes on the
chromosome.ancer Cell 16, 475–486, December 8, 2009 ª2009 Elsevier Inc. 475
Cancer Cell
Aneuploidy Causes Cancer by p53 or Apc LOHintact, gene copy is inactivated by a whole chromosome loss
during an aberrant mitosis. One study examined this mechanism
by crossing mice with only one functional copy of p53 or Rb onto
a heterozygous null genetic background for the mitotic check-
point gene Bub3. However, no increase in tumorigenesis was
observed in this analysis (Kalitsis et al., 2005). Another study
found that colon tumor development increased when ApcMin/+
mice had only one copy of the mitotic checkpoint protein
BubR1, but whether this increase was associated with acceler-
ated loss of heterozygosity (LOH) of the Apc+ locus is not
known (Rao et al., 2005). The same holds true for a study of
p53 and Mad2 double-heterozygous null mice (Chi et al.,
2009). These mice showed increased lymphomagenesis, but
whether this increase was linked to p53 LOH was not deter-
mined. It has also been proposed that chromosomal instability
may not drive tumorigenesis by LOH of tumor suppressor genes
(Weaver and Cleveland, 2007). This suggestion was based on
the observation that aneuploidy resulting from Cenp-E haploin-
sufficiency delayed tumor formation when both copies of the
p19Arf tumor suppressor gene are lacking.
Given the complex relationship between numerical chromo-
some segregation and tumorigenesis, it will be important to
address the question as to whether inaccurate chromosome
segregation drives tumorigenesis through tumor-suppressor
gene LOH in a comprehensive fashion. The mitotic checkpoint
protein Bub1, which is mutated or expressed at low levels in
a subset of human cancers (Yuen et al., 2005), has been causally
implicated in cancer (Jeganathan et al., 2007; Schliekelman
et al., 2009). Mice in which expression of Bub1 is gradually
reduced using various combinations of wild-type, hypomorphic,
and knockout Bub1 alleles develop spontaneous tumors with
reduced latency and increased incidence in a dose-dependent
fashion (Jeganathan et al., 2007). We reasoned that, using this
series of mice in combination with different heterozygous tumor
suppressor gene mutant mice, would not only allow for compre-
hensive analysis of the issue as to whether aneuploidy can
promote tumorigenesis through tumor suppressor gene LOH,
but also help us understand how the degree of chromosomal
instability impacts this mechanism. The tumor suppressor genes
that we selected are p53, Rb, Apc, and Pten, which are located
on mouse chromosomes 11, 14, 18, and 19, respectively.
RESULTS
Bub1 Insufficiency Causes Thymic Lymphomagenesis
in p53+/– Mice
Mice with two inactivated copies of p53 typically develop lethal
thymic lymphomas within the first 9 months of life (Jacks et al.,
1994). p53 heterozygous null mice are also prone to tumors,
primarily sarcomas. However, these tumors rarely surface within
the first year of life. The majority of tumors in p53+/– mice display
loss of heterozygosity of the remaining wild-type allele, suggest-
ing that a critical barrier to neoplastic growth is established by
retention of this wild-type allele. To determine whether chromo-
somal instability can decrease the tumor latency in p53+/– mice
by accelerating loss of the wild-type p53 allele, we used amouse
series with graded reduction in Bub1 expression. We have previ-
ously shown that Bub1 expression inversely correlates with
aneuploidy in mouse embryonic fibroblasts (MEFs) and mouse476 Cancer Cell 16, 475–486, December 8, 2009 ª2009 Elsevier Incsplenocytes (Jeganathan et al., 2007). Furthermore, chromo-
some counts on various kinds of cultured primary cells from
Bub1 mutant mice, including vascular smooth muscle cells,
lung fibroblasts, mammary gland epithelial cells, and prostate
cells, suggests that increased aneuploidy is likely to be a
common consequence of Bub1 insufficiency (see Figure S1
available online). Through two rounds of breeding, we estab-
lished cohorts of p53+/–, Bub1+/H/p53+/– (75% of normal
Bub1 levels), Bub1+/–/p53+/– (50% Bub1), Bub1H/H/p53+/–
(30%Bub1), andBub1–/H/p53+/– (20%Bub1) mice andmoni-
tored these mice for development of overt tumors or signs of ill
health for up to 600 days. Bub1+/H/p53+/– and Bub1+/–/p53+/–
mice showed similar survival as p53+/– mice. However, survival
of Bub1H/H/p53+/– and Bub1–/H/p53+/– mice was markedly
decreased, with the latter mice showing the most dramatic
reduction (Figure 1A). Tumor-free survival curves revealed that
decreased survival was due to tumor development (Figure 1B).
The tumor incidence in Bub1H/H/p53+/– and Bub1–/H/p53+/–
mice was significantly increased, whereas the average tumor
latency was considerably decreased (Figure 1C). In contrast,
no such changes were observed in Bub1+/–/p53+/– and Bub1+/H/
p53+/– mice. Strikingly, Bub1H/H/p53+/– and Bub1–/H/p53+/– mice
were almost exclusively predisposed to the development of
thymic lymphoma, a tumor type that was not observed in
p53+/– mice and only at low rates in Bub1H/H and Bub1–/H single
mutant mice (Figure 1D). Thymic lymphomas arose significantly
earlier in Bub1–/H/p53+/– mice than in Bub1H/H/p53+/– mice, with
a mean time to tumor onset of 163 and 314 days, respectively
(p = 0.0004). The most common tumors observed in p53+/–
animals are sarcomas (Jacks et al., 1994), but the incidence
and latency with which these tumors formed were unaffected
by Bub1 protein levels (Figure 1E). These results indicate that
the level of Bub1 needs to drop below a critical threshold in order
to progressively promote tumorigenesis in p53 heterozygous
mice, and that thymic T cells are particularly sensitive to this
decline in Bub1.
Low Bub1 Promotes p53 LOH through Whole
Chromosome Missegregation
The tumor profile that we observed in Bub1–/H/p53+/– mice is
similar to that of p53–/– mice (Jacks et al., 1994). A potential
mechanism underlying this similarity might be that the high rate
of chromosomal missegregation resulting from low Bub1
expression dramatically increases the frequency of loss of the
chromosome containing the remaining wild-type p53 allele. To
test this hypothesis, nine thymic lymphomas from Bub1–/H/
p53+/– mice were screened for p53 status using a previously
established PCR method (Jacks et al., 1994). In all instances,
we found that the PCR fragment representing wild-type p53
was either highly underrepresented or completely absent
(Figure 2A). Southern blot analysis of the same set of tumors
confirmed the absence of wild-type p53 (Figure 2B), indicating
that Bub1–/H/p53+/– thymocytes that develop into lethal tumors
consistently lose wild-type p53. Thymic lymphomas from
Bub1H/H/p53+/– animals also lacked wild-type p53 (data not
shown), lending further support to the notion that p53 LOH is
a requisite for tumorigenesis to occur in the thymus.
Given that Bub1 insufficiency causes chromosome missegre-
gation (Jeganathan et al., 2007), the simplest explanation for the.
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Aneuploidy Causes Cancer by p53 or Apc LOHFigure 1. Bub1 Insufficiency Synergizes
with p53 Haploinsufficiency in T Cell Lym-
phomagenesis
(A) Kaplan-Meier overall survival curves of p53+/,
Bub1+/H/p53+/,Bub1+//p53+/,Bub1H/H/p53+/,
Bub1/H/p53+/, Bub1+/H, Bub1+/, Bub1H/H, and
Bub1/H mice Bub. *p < 0.05 compared to p53+/–
mice (log rank test). Mice in these cohorts were
monitored for 600 days. Animals represented in
thecurvesaremice that diedor that had tobesacri-
ficed because of ill health or overt tumors. Cohorts
of Bub1+/–, Bub1H/H, and Bub1–/H mice are as
described elsewhere (Jeganathan et al., 2007).
(B) Kaplan-Meier tumor-free survival curves of
mice presented in (A). Animals that died without
tumors were censored from the data. We note
that the percentage of p53+/– animals dying
without tumors was similar to that previously
reported for this strain (Jacks et al., 1994). *p <
0.05 compared to p53+/– mice (log rank test).
Legend is as in (A).
(C) Tumor incidence and average tumor latency of
mice shown in (A). *p < 0.05 versus p53+/– mice
(Fisher’s exact test for incidence; log rank test
for latency). **These cohorts were monitored for
1000 days, instead of 600 days.
(D) Kaplan-Meier curves showing the thymic
lymphoma-free survival of mice presented in (A).
*p < 0.05 compared to p53+/– mice (log rank
test). Legend is as in (A).
(E) Same as (D) with sarcoma incidence plotted.
Legend is as in (A). We note that for groups hetero-
zygous for p53, after 500 days no individual group
had more than 10 animals at risk for developing
neoplasia. The large steps that appear during late
age are because individual tumors that occurred
in these small sample size groups reflect larger
proportional changes. Furthermore, note that all
Bub1H/H/p53+/– and Bub1–/H/p53+/– mice in the
study died before 600 days. Therefore, the curves
for these animal groups in (B), (D), and (E) do not
extend to 600 days. Tick marks indicate censored
animals in curves plotted in (B), (D), and (E).observed p53 LOH would be that the copy of chromosome 11
containing the wild-type p53 allele gets lost during an aberrant
cell division. To test for this possibility, we performed spectral
karyotype (SKY) analysis on three independent lymphomas
from Bub1–/H/p53+/– mice. We found that all of the spreads
examined had two chromosome 11 copies, instead of one
(Figure 2C, panels 1–5). This finding, combined with our
Southern data, suggested that instead of simply losing chromo-
some 11 bearing wild-type p53, lymphoma cells had gained an
extra copy of chromosome 11 harboring the knockout allele.
This might have occurred in one step through nondisjunction of
the mutant chromosome pair and coincidental loss of the
chromosome carrying wild-type p53 or in two separate cell
divisions: loss of chromosome 11 carryingwild-typep53 followed
by a gain of chromosome 11 containing mutant p53, or vice
versa. However, two alternative mechanisms that could explain
the presence of two chromosome 11 copies containing the
knockout allele are mitotic recombination and gene conversion.
To determine whether these mechanisms might be involved,
we performed simple sequence length polymorphism (SSLP)
analysis on a series of thymic lymphomas from Bub1–/H/p53+/–Cmice. We selected six SSLPmarkers along the 0–36.1 cM region
of chromosome 11 (Figure 3). Three of these markers were
informative on normal tail DNA from eight lymphoma-positive
Bub1–/H/p53+/– mice. Corresponding lymphoma DNA samples
from these mice were then subjected to the same analysis. In
all of these tumors, we observed LOH at all informative SSLP
markers (Figure 3), indicating that whole chromosomemissegre-
gation, rather than mitotic recombination, was responsible for
p53 LOH. Thus, mitotic recombination and gene conversion,
two alternativemechanisms bywhich cells could become homo-
zygous for an inactivate tumor suppressor gene, are unlikely to
drive p53 LOH in our Bub1–/H/p53+/– model.
To determine the degree of aneuploidy in lymphomas of
Bub1–/H/p53+/– mice, we performed chromosome counts on
metaphase spreads of six independent thymic tumors. On
average, 56% of tumor cells were aneuploid, with most cells
losing or gaining one or several chromosomes (near diploid)
and some cells gaining more than 10 chromosomes (Table 1).
SKY data confirmed that a substantial proportion of tumor cells
had 40 chromosomes (Figure 2C, panels 1 and 2). Some of these
cells had completely normal karyotypes (Figure 2C, panel 1), butancer Cell 16, 475–486, December 8, 2009 ª2009 Elsevier Inc. 477
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Aneuploidy Causes Cancer by p53 or Apc LOHFigure 2. p53 LOH in Lymphomas from Bub1–/H/p53+/– and Bub1H/H/
p53+/– Mice
(A) p53 status of lymphomas from Bub1–/H/p53+/– mice analyzed by PCR.
Genomic DNA samples prepared from thymus of 6-week-old p53+/+, p53+/–,
and p53–/– mice were used as PCR controls.
(B) Analysis of the p53 status of lymphomas shown in (A) using Southern blot-
ting as described elsewhere (Jacks et al., 1994). Genomic DNA samples
prepared from thymus of 6-week-old p53+/+ and p53+/– mice were used as
controls.
(C) Spectral karyotype analysis of lymphoma cells harvested from a represen-
tative Bub1–/H/p53+/– mouse. Shown are examples of cells (from the same
tumor) that: (1) are karyotypically normal; (2) have 40 chromosomes but are
karyotypically abnormal; (3 and 4) have minor numerical abnormalities (upper478 Cancer Cell 16, 475–486, December 8, 2009 ª2009 Elsevier Incaccording to our LOH analysis, these cells had to have two
copies of the p53 knockout allele (Figures 2A and 2B). Other cells
with 40 chromosomes had nonmodal numbers of specific chro-
mosomes (Figure 2C, panel 2), indicating that our chromosome
counts onmetaphase spreads underrated the incidence of aneu-
ploidy. Thymic lymphomas from Bub1–/H/p53+/– had remarkably
similar rates of aneuploidy as thymic lymphomas from p53–/–
(Table 1), indicating that cells with low levels of Bub1 do not
necessarily produce cancer cells with more profound aneu-
ploidy. Chromosome counts on metaphase spreads from
healthy 5-month-old p53+/– and Bub1–/H/p53+/– mice, however,
demonstrated that Bub1 insufficiency strongly accelerates
chromosome missegregation in nontransformed p53+/– cells
(Table 1). We note that, even though the percentage of aneuploid
splenocytes was relatively high in Bub1–/H/p53+/– mice, it was
considerably lower than that of Bub1–/H mice (19% versus
39%; Jeganathan et al., 2007). The reason for this is currently
unclear. Collectively, the above data suggest that loss of chro-
mosome 11 containing wild-type p53 followed by (or coinciding
with) gain of chromosome 11 containing the knockout p53 allele
is a key mechanism by which Bub1 insufficiency drives thymic
lymphomagenesis in p53+/– mice.
Although p53 LOH is not a prerequisite for sarcomagenesis in
p53+/– mice, the p53wild-type allele is either absent or underrep-
resented in most sarcomas that develop in these mice (Jacks
et al., 1994). The number of chromosome 11 copies in sarcomas
with p53 LOH, however, is unknown. To test for this, we first
screened six sarcomas from p53+/– mice for p53 LOH by
Southern blot analysis and identified four sarcomas with little
or no wild-type p53 (Figure S2A). Like lymphomas from Bub1–/H/
p53+/– mice with two chromosome 11 copies harboring the p53
knockout allele, the p53 knockout allele was highly overrepre-
sented in these sarcomas (Figure S2A), indicating that the
knockout allele was duplicated. To examine this further, we
performed interphase FISH for chromosome 11 on paraffin
sections from these tumors. The percentage of cells with two
chromosome 11 signals was 80% or more for each tumor, which
was the same as for nontumor tissue (Figures S2B and S2C).
Collectively, these data demonstrate that sarcomas that lose
the wild-type copy of p53 retain two copies of chromosome 11,
suggesting that there is selective pressure against cells losing
a copy of this chromosome.
Bub1 Hypomorphism Selectively Drives Colon
Tumorigenesis in ApcMin/+ Mice
We wondered whether Bub1 insufficiency would also promote
tumorigenesis in other heterozygous tumor-suppressor models
that rely on LOH, such as the ApcMin/+ mousemodel for intestinal
cancer (Luongo et al., 1994). This model is particularly attractive
for further study, becauseBub1 is eithermutated or expressed at
low levels in a subset of human colon carcinomas (Lengauer
et al., 1997; Shichiri et al., 2002). Because tumor penetrance in
right and lower left); or, (5) exhibit combined numerical and structural chromo-
some changes (lower right). About 10–11% of tumor cells of three independent
lymphomas had structural chromosome changes, which is to be expected for
cells that lack p53, a key regulator of genome maitenance. Note that all cells
have two copies of chromosome 11 (see red squares)..
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Aneuploidy Causes Cancer by p53 or Apc LOHApcMin/+ mice is dependent on the genetic background, we
backcrossed Bub1–/H mice to C57BL/6 mice for 10 generations
before breeding them to ApcMin/+ C57BL/6 mice. Cohorts of
Bub1+/H/ApcMin/+, Bub1+/–/ApcMin/+, Bub1–/H/ApcMin/+, Bub1+/–,
Bub1–/H, and ApcMin/+ mice were established, and, at 90 days,
mice were sacrificed and screened for intestinal tract polyps.
Consistent with the literature, ApcMin/+ mice developed small
intestinal tumors with 100% incidence (Figure 4A). On average,
these mice had 55 small intestinal tumors (Figure 4B). We
Figure 3. p53LOH inLymphomasofBub1–/H/
p53+/– Mice Occurred by Loss of Chromo-
some 11 Harboring the p53+ Locus
Haplotypes of lymphomas and matched tail
(normal) tissue from Bub1–/H/p53+/– mice.
found that the number of small intestinal
tumors did not change with decreasing
amounts of Bub1 (Figures 4A and 4B),
demonstrating that low amounts of
Bub1 are not capable of promoting small
intestinal tumorigenesis. In striking con-
trast, however, tumor formation in the
large intestine strongly increased with
decreasing Bub1 levels. Although colon
tumors were observed in 30% of ApcMin/+
mice, 88% of Bub1+/–/ApcMin/+ mice and
100% of Bub1–/H/ApcMin/+ mice had such tumors (Figure 4A).
In addition, Bub1+/–/ApcMin/+ and Bub1–/H/ApcMin/+ mice had
on average 8- and 23-fold more tumors than did ApcMin/+
mice, respectively (Figures 4C and 4E). Typically, colon tumors
of Bub1–/H/ApcMin/+ were largest in size (Figures 4D and 4E).
Interestingly, colon tumor incidence and burden were not
affected in Bub1+/H/ApcMin/+ mice (Figures 4A–4D), indicating
that accelerated colonic tumorigenesis requires a certain









Figures Karyotypes with Indicated Chromosome Number
31 32 33 34 35 36 37 38 39 40 41 42 43 44 46 >50
Bub1–/H/p53+/– thymic lymphoma 1 55 45 1 1 2 2 1 3 1 30 7 7
thymic lymphoma 2 50 54 1 2 6 9 23 2 1 6
thymic lymphoma 3 52 65 1 1 2 2 1 7 4 18 6 2 1 7
thymic lymphoma 4 98 51 2 2 1 2 3 4 13 48 20 3
thymic lymphoma 5 50 56 1 3 2 1 4 6 22 6 1 1 3
thymic lymphoma 6 54 63 2 1 1 3 6 12 20 3 3 1 2
p53–/– thymic lymphoma 1 51 55 1 3 4 8 23 4 3 5
thymic lymphoma 2 49 61 2 4 4 4 6 19 2 3 1 4
thymic lymphoma 3 55 62 1 1 3 1 7 10 21 1 1 1 8
p53+/+ spleen 1 (5 mo) 50 0 50
spleen 2 (5 mo) 50 0 50
spleen 3 (5 mo) 50 0 50
p53+/– spleen 1 (5 mo) 49 6 1 46 2
spleen 2 (5 mo) 38 11 3 34 1
spleen 3 (5 mo) 19 5 1 18
Bub1–/H/p53+/– spleen 1 (5 mo) 18 17 1 1 1 15
spleen 2 (5 mo) 47 23 1 2 1 1 5 36 1
spleen 3 (5 mo) 67 18 1 3 3 4 55 1
p53+/+ testis 1 (5 mo) 50 0 50
testis 2 (5 mo) 50 0 50
Bub1–/H testis 1 (5 mo) 50 0 50
testis 2 (5 mo) 50 0 50Cancer Cell 16, 475–486, December 8, 2009 ª2009 Elsevier Inc. 479
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Aneuploidy Causes Cancer by p53 or Apc LOHKaryotype analysis showed that splenocytes from ApcMin/+
mice had moderately increased aneuploidy over wild-type sple-
nocytes (Figure 5A), which is in accordance with earlier studies
reporting elevated aneuploidy rates in cultured ApcMin/+ MEFs
and ES cells (Fodde et al., 2001; Kaplan et al., 2001; Rao et al.,
2005). However, relative to ApcMin/+ splenocytes, the percent-
ages of aneuploidy in Bub1+/–/ApcMin/+ and Bub1–/H/ApcMin/+
splenocytes were dramatically increased (18% and 41%,
respectively; see Figure 5A). Interestingly, aneuploidy rates of
Bub1–/H/ApcMin/+ compound mutant mice were significantly
higher than the rates of Bub1–/H and ApcMin/+ single mutants
combined (46% versus 38%), indicating that Bub1 and Apc
synergize in chromosome missegregation. The exact same
phenomenonwasobserved inBub1+/–/ApcMin/+mice (Figure 5A).
The above data suggest that Bub1 insufficiency accelerates the
rate at which whole chromosomes are lost or gained in ApcMin/+
mice, thereby perhaps accelerating Apc LOH and driving colonic
tumorigenesis. To test for LOH at the Apc locus, we collected
colon tumors (T) of several Bub1–/H/ApcMin/+ mice and analyzed
these tumors for thepresenceof theApc+allele usingapreviously
establishedPCR-basedassay.Normal tissue flanking eachof the
tumors (N) was used as a control. We found that the remaining
Figure 4. Colon Tumor Formation Dramati-
cally Increases in ApcMin/+ Mice when
Bub1 Levels Decline
(A) Small intestine and colon tumor incidences in
mutant mice of the indicated genotypes. Bub1
mutant strains not bred onto an ApcMin/+ back-
ground did not develop any intestinal tumors.
*p < 0.05 compared to ApcMin/+ mice (Fisher’s
exact test).
(B) Small intestine tumor multiplicity. Color codes
are as indicated in (A). Data are mean ± SEM.
(C) Colon tumor burden. Color codes are as indi-
cated in (A). Data are mean ± SEM. *p < 0.05
compared to ApcMin/+ mice (unpaired t test).
(D) Mean size of colon tumors. Data are mean ±
SEM. *p < 0.05 compared to ApcMin/+ mice
(unpaired t test).
(E) Colonic tumors in ApcMin/+ and Bub1–/H/
ApcMin/+ mice. Top: Colons were stained with
methylene blue. Hatched yellow lines surround
individual colon tumors. Bottom: Hematoxylin-
eosin–stained sections of colon tumors from
ApcMin/+ and Bub1–/H/ApcMin/+ mice. Bars repre-
sent 2 mm.
Apc wild-type allele was lost in 100% of
tumors examined (Figure 5B). To investi-
gate whether Apc LOH was due to loss
of the chromosome 18 copy containing
the wild-type Apc allele, we performed
interphase FISH on colon tumor sections
of Bub1–/H/ApcMin/+ mice using centro-
meric and telomeric chromosome 18
probes. The vast majority of colon tumor
cells had two copies of chromosome 18
(Figure 5C), suggesting that colon tumors,
similar to thymic lymphomas of Bub1–/H/
p53+/– mice, have a duplication of the
mutant allele. Given that Bub1 is a whole chromosome instability
gene, it is reasonable to assume that this duplication occurred
through a gain of whole chromosome 18 containing the ApcMin
allele. The mice were on a pure C57BL/6 genetic background,
precluding the use of SSLP analysis to fully prove this. The only
alternative mechanism through which the ApcMin allele might
have been duplicated is mitotic recombination. However, this
mechanism is unlikely because sister chromatid exchange
(SCE) analysis on Bub1–/H and wild-type MEFs revealed that
Bub1 insufficiency has no impact on the rate of mitotic recombi-
nation (Figures S3A and S3B). Interphase FISH analysis for
chromosomes 4 and 7 on cells from collagenase-treated
Bub1–/H/ApcMin/+ colon tumors provided evidence for significant
chromosome reshuffling (Figures S3C–S3E), further supporting
that Bub1 insufficiency drives colon tumor formation in ApcMin/+
mice by inducing loss of chromosome 18 containing the APC+
allele and gain of chromosome 18 bearing the ApcMin allele.
Bub1 Insufficiency Has No Effect on Tumorigenesis
in Rb+/– Mice
Mice in which one allele of Rb is disrupted develop pituitary
tumors at nearly 100% incidence (Jacks et al., 1992; Lee480 Cancer Cell 16, 475–486, December 8, 2009 ª2009 Elsevier Inc.
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Aneuploidy Causes Cancer by p53 or Apc LOHet al., 1992). These tumors invariably lose expression of Rb
protein as a result of loss of the remaining wild-type Rb allele
(Hu et al., 1994). To determine the impact of whole chromosome
instability resulting from low Bub1 on tumor development in this
animal model, cohorts of Rb+/–, Bub1–/H/Rb+/–, Bub1–/H and
wild-type mice were generated and monitored. In contrast to
our observations in p53+/– and ApcMin/+ mice, low Bub1 levels
had absolutely no impact on tumor development in Rb+/– mice.
As shown in Figure 6A, the tumor-free survival curves of Rb+/–
and Bub1–/H/Rb+/– mice were almost completely overlapping.
Consistent with earlier studies (Jacks et al., 1992; Lee et al.,
1992), Rb+/– mice developed primarily pituitary tumors and an
occasional sarcoma (Figure 6B). Although the incidence of
pituitary tumors in Bub1–/H/Rb+/– mice was somewhat lower
than inRb+/–mice (Figure 6B), this difference did not reach statis-
tical significance.
Pituitary tumors of Rb+/– and Bub1–/H/Rb+/– mice consis-
tently lacked the wild-type allele of Rb (Figure 6C), indicating
that, both with and without Bub1 insufficiency, Rb LOH is
a requisite for tumor formation. Reduced levels of Rb leads
to up-regulation of E2F target genes, including some mitotic
regulators (Bracken et al., 2004). A trivial explanation for the
lack of accelerated tumorigenesis might therefore be that Rb
loss counteracts Bub1 insufficiency. However, Western blotting
confirmed that both normal tissue and pituitary tumors of
Bub1–/H/Rb+/– mice were hypomorphic for Bub1 (Figure 6D).
Consistent with this, we observed much higher percentages
of aneuploid splenocytes in Bub1–/H/Rb+/– mice than in
Figure 5. Apc LOH in Colon Tumors from
Bub1–/H/ApcMin/+ Mice
(A) Chromosome counts on splenocytes of
3-month-oldwild-type,Bub1+/–,Bub1–/H,ApcMin/+,
Bub1+/–/ApcMin/+, and Bub1–/H/ApcMin/+ mice.
(B) PCR-based screening for Apc LOH in colon
tumors from Bub1–/H/ApcMin/+. Tail DNA samples
from wild-type and ApcMin/+ mice were used as
PCR controls. Note that colon tumors from
Bub1–/H/ApcMin/+ mice consistently show prefer-
ential amplification of the ApcMin allele, indicating
loss of the Apc+ allele.
(C) Interphase FISH image of a 5 mm colon tumor
section of a Bub1–/H/ApcMin/+ mouse hybridized to
both centromeric (red) and telomeric (green) chro-
mosome probes. Quantification of the chromo-
some 18 copies in colon cancer cells and flanking
normal colon epithelial cells. FISH signals of one
hundred cells were counted per section. Scale
bar is 5 mm.
Rb+/– mice (Figure 6E). We were unable
to detect significant aneuploidy in pitui-
tary tumors by interphase FISH on
paraffin sections (Figure S4A). However,
it is important to note that we find that
interphase FISH on paraffin sections is
not sensitive enough to detect near
diploid aneuploidies such as those
induced by Bub1 insufficiency (Figures
S4B–S4D). Therefore, it cannot be concluded that these
tumors are not aneuploid.
Bub1 Loss Suppresses Prostatic Intraepithelial
Neoplasia in Pten+/– Mice
Pten LOH is a common event in human prostate cancer (Di Cris-
tofano and Pandolfi, 2000). This, combined with the observation
that chromosomal instability increases with prostate cancer
grade in humans (Hawkins et al., 1995), prompted us to test
whether theBub1–/H genotypemight driveprostate cancer devel-
opment in Pten+/– mice (Di Cristofano et al., 2001; Podsypanina
et al., 1999). To this end, small cohorts of Pten+/– and Bub1–/H/
Pten+/– males were generated and sacrificed at 6 months of
age. Whole prostates were dissected and screened for overt
prostate tumors using a dissection microscope; however, no
such tumors were detected irrespective of genotype. Following
fixation, prostates were serially sectioned and screened for PIN
II, III, and IV lesions (Park et al., 2002). Strikingly, Bub1–/H/
Pten+/– mice had about 40% fewer PIN II and III lesions than did
Pten+/– mice (Figure 7A). On the other hand, the numbers of PIN
IV lesionswere very similar between the two genotypes, although
it should be noted that the number of mice in the study is
insufficient to detect potential differences. No PIN II, III, or IV
lesions were observed in 6-month-old Bub1–/H males (data not
shown). Immunohistochemisty on paraffin sections of Pten+/–
and Bub1–/H/Pten+/– prostates revealed that Pten is either unde-
tectable or barely detectable inPIN II lesions, irrespective ofBub1
level of expression (Figure 7B).Cancer Cell 16, 475–486, December 8, 2009 ª2009 Elsevier Inc. 481
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of Bub1 insufficiency during the early stages of prostate tumor-
igenesis, we prepared metaphase spreads of splenocytes of
Pten+/–, Bub1–/H, and Bub1–/H/Pten+/– mice and performed
chromosome counts. We noticed that loss of a single Pten allele
was associated with high rates of aneuploidy, with 19% of
Pten+/– splenocytes exhibiting aneuploidy, compared with 0%
of splenocytes of control mice (Figure 7C), indicating that a full
complement of Pten is required for accurate chromosome
segregation. Strikingly, 80% of aneuploid Pten+/– splenocytes
had fewer than 40 chromosomes, indicating a strong bias toward
loss of chromosomes. Importantly, Bub1–/H/Pten+/– splenocytes
showed remarkably high rates of chromosome missegregation,
with 75–84% of splenocytes being aneuploid, much higher
than the percentages of Bub1–/H and Pten+/– single mutants
combined (Figure 7C). Notably, 83% of aneuploid splenocytes
of double mutant mice contained more than 40 chromosomes,
which contrasts the preferential chromosome losses observed
in Pten+/– animals. Furthermore, spreads from Bub1–/H/Pten+/–
double mutants had a much broader spectrum of abnormal
chromosome numbers than did spreads from Bub1–/H and
Pten+/– single mutants (Figure 7C). These data imply that Bub1
and Pten might act synergistically in preventing chromosome
Figure 6. Tumorigenesis in Rb+/– Mice Is
Not Impacted by Bub1 Insufficiency
(A) Kaplan-Meier tumor-free survival curves of
Rb+/–, Bub1–/H/Rb+/–, Bub1–/H, and wild-type
mice. Curves of Rb+/– and Bub1–/H/Rb+/– mice
are not significantly different from each other (log
rank test).
(B) Tumor spectrum of mice represented in (A).
There were no statistically significant changes in
tumor spectrum between the Rb+/ mouse
cohorts (Fisher’s exact test).
(C) PCR-based screening for Rb LOH in pituitary
tumors from Rb+/– and Bub1–/H/Rb+/– mice. As
controls, we used DNA samples from flanking
normal brain tissue and brain DNA samples of
wild-type and Bub1–/H mice.
(D) Western blot analysis of normal brain (N) and
pituitary tumors (T) of Rb+/– and Bub1–/H/Rb+/–
animals. Note that Bub1, but not the Bub1-related
protein BubR1, was expressed at reduced levels
in both normal and tumor tissues of Bub1–/H/
Rb+/– mice. Tubulin was used as a loading control.
(E) Chromosome counts on splenocytes of
5-month-old Rb+/–, Bub1–/H/Rb+/– and Bub1–/H
mice.
missegregation. Because of the limited
sensitivity of interphase FISH on paraffin
sections, we were unable to determine
the precise ploidy status of neoplastic
prostate epithelial cells of Bub1–/H/
Pten+/– mice. However, interphase FISH
for chromosomes 4 and 7 did indicate
that cells of PIN II-IV lesions had no near
tetraploid aneuploidies (Figure S5A).
Cell death has previously been linked to
chromosomal instability (Dobles et al.,
2000; Kops et al., 2004) and might underlie, at least in part, the
decrease in prostate tumorigenesis in double mutant males. To
test for this possibility, we screened the various PIN lesions of
Pten+/–/Bub1–/H and Pten+/– mice for the presence of pyknotic
nuclei. These nuclei are indicative of apoptosis and can be easily
identified in hematoxylin and eosin–stained paraffin sections.
Strikingly, significant increases in pyknotic nuclei were observed
in PIN II and III lesions of Pten+/–/Bub1–/H mice, but not in PIN IV
lesions (Figure 7D). It has further been suggested that aneuploidy
can impair cell proliferation and, as such, inhibit tumorigenesis
(Torres et al., 2007; Torres et al., 2008; Williams et al., 2008).
To screen for reduced cell proliferation, we stained paraffin
sections ofBub1–/H/Pten+/– andPten+/– prostates for the prolifer-
ation marker PCNA. As illustrated in Figure 7E, Bub1–/H/Pten+/–
PIN II and PIN III lesions, but not PIN IV lesions, always had fewer
PCNA-positive cells than did corresponding Pten+/– lesions. To
confirm this growth inhibitory effect of Bub1 insufficiency, we
performed an in vivo BrdU labeling experiment. We injected
6-month-old Bub1–/H/Pten+/– and Pten+/– males with BrdU,
collected their prostates 24 hr later, and prepared paraffin
sections, which we stained for BrdU. As expected, Bub1–/H/
Pten+/– PIN II and PIN III lesions, but not PIN IV lesions, contained
far fewer BrdU-positive cells than did equivalent lesions of482 Cancer Cell 16, 475–486, December 8, 2009 ª2009 Elsevier Inc.
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Aneuploidy Causes Cancer by p53 or Apc LOHPten+/– mice (Figures S5B and S5C). Collectively, these data
suggest that decreased proliferation and increased cell death
may, at least in part, underlie the tumor suppressive effect of
Bub1 insufficiency in prostate of Pten+/– mice. Furthermore,
they suggest that, during the early stages of tumor evolution,
there is a selective pressure to counteract the adverse effect of
Bub1 insufficiency on cell growth and survival.
DISCUSSION
Whole Chromosomal Instability, Tumor Suppressor
Gene LOH, and Tumorigenesis
Five observations in p53+/– mice with reduced Bub1 levels
provide conclusive experimental evidence for the longstanding
hypothesis that whole chromosome instability can drive tumori-
genesis by promoting tumor suppressor gene LOH. First, p53+/–
mice become highly prone to thymic lymphomas when the rate
Figure 7. Low Bub1 Decreases Early PIN
Lesions in Pten+/– Males
(A) At 6 months, Pten+/– males have significantly
more PIN II and III lesions than age-matched
Bub1–/H/Pten+/– mice. *p = 0.0017; **p = 0.0186
(unpaired t tests comparing similar grade PIN
lesions). Data represented are mean ± SD. PIN IV
multiplicity was similar for Pten+/– and Bub1–/H/
Pten+/– males.
(B) PIN II lesions of 6-month-old Pten+/– and
Bub1–/H/Pten+/– males analyzed for Pten by immu-
nohistochemistry. Pten was either undetectable
(shown) or barely detectable (not shown) in PIN II
lesions of both mouse strains. Normal prostate
epithelium of aPten+/– male was used as a positive
control for Pten staining. Scale bar is 100 mm.
(C) Pten+/– and Bub1–/H genotypes strongly syner-
gize in causing chromosome missegregation in
splenocytes. Chromosome counts were per-
formed on splenocytes of 5-month-old mice of
the indicated genotypes.
(D) Analysis of dead cells in PIN lesions of Pten+/–
and Bub1–/H/Pten+/– animals (at 6 months). Top:
High resolution image of a hematoxylin and
eosin–stained section of a PIN II lesion from
a Bub1–/H/Pten+/– male showing cells with highly
condensed pyknotic nuclei with halo like appear-
ance. Bottom: Quantification of pyknotic nuclei in
various PIN lesions of Pten+/– and Bub1–/H/
Pten+/– animals. n = 270 PIN II, 100 PIN III, and
12 PIN IV lesions per genotype. Data presented
are mean ± SD. *p < 0.01 and **p < 0.05 (unpaired
t test). Scale bar represents 10 mm.
(E) Analysis of cell proliferation in various PIN
lesions of 6-month-old Pten+/– and Bub1–/H/
Pten+/– males by immunohistochemistry for PCNA
(n = 3 mice per genotype). Scale bar is 100 mm.
of chromosome missegregation is accel-
erated by Bub1 hypomorphism. Second,
these tumors consistently show loss of
the chromosome 11 copy containing the
wild-type p53 allele. Unexpectedly, the
loss of this chromosome was always
accompanied by a gain of an extra copy
of the chromosome harboring the inactivated p53 allele. It has
been proposed that loss of an entire chromosome will lead to
underexpression of various genes located on that chromosome,
which has been linked to cellular stress and reduced proliferation
(Torres et al., 2007; Torres et al., 2008; Williams et al., 2008).
Thus, the consistent presence of two chromosome copies con-
taining the targeted p53 allele might reflect an early selective
pressure to counteract growth inhibitory stress associated with
the loss of one copy of chromosome 11. Although the mecha-
nism by which the lymphoma cells obtain two copies of the chro-
mosome containing the targeted p53 allele most likely involves
multiple steps, occurring in consecutive cell divisions, it theoret-
ically could also occur in a single division. For instance, because
of syntelic microtubule-kinetochore attachment, both chromo-
some 11 copies containing knockout p53 may be pulled toward
one pole and those harboring wild-type p53 toward the other.
This scenario cannot be excluded, given that Bub1 functions inCancer Cell 16, 475–486, December 8, 2009 ª2009 Elsevier Inc. 483
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ciency increases the rate of congression failure (Jeganathan
et al., 2007; Meraldi and Sorger, 2005; Perera et al., 2007). Third,
besides two copies of chromosome 11 containing the p53–
allele, lymphoma cells from Bub1–/H/p53+/– mice lack recurrent
numerical changes of particular chromosomes, supporting the
idea that the main tumorigenic effect of chromosomal instability
resulting from Bub1 loss is to drive p53 LOH. Fourth, lymphoma-
genesis in p53+/– mice inversely correlates with Bub1 level of
expression. This, combined with the observation that aneuploidy
also has an inverse relationship with Bub1 amount (Jeganathan
et al., 2007), suggests that the rate with which chromosomes
are reshuffled during cell division determines the rate with which
cells undergo LOH and become tumor prone. Fifth, sarcomagen-
esis is the primary neoplastic process observed in p53+/– mice,
but when Bub1 levels of thesemice drop below a threshold level,
tumorigenesis shifts toward development of thymic lymphomas,
the most prevalent tumor type seen in p53–/– mice (Jacks et al.,
1994). This shift suggests that thymuses of p53+/– mice with low
amounts of Bub1 accrue p53–/– thymocytes at high rates as
a result of chromosome missegregation, thereby increasing the
risk of neoplastic transformation in this organ.
Furthermore, our analysis of colon tumors from Bub1–/H/
ApcMin/+ mice provides evidence suggesting that Bub1 drives
tumorigenesis through a similar chromosome-reshuffling blue-
print in colon epithelial cells, but now involving chromosome
18 containing the Apc gene locus. Because of the pure C57BL/6
genetic background of the Bub1–/H/ApcMin/+ mice, SSLP anal-
ysis could not be used to prove that colon cancer cells had
obtained two copies of chromosome 18 containing the ApcMin
allele through whole chromosome missegregation. However,
mitotic recombination, themost plausible alternativemechanism
by which these chromosomes could have been obtained, is
unlikely because SCE analysis on wild-type and Bub1–/H cells
revealed that Bub1 insufficiency does not alter the frequency
with which this type of recombination occurs.
Although there are no known functions forBub1other thanpro-
tecting cells against aneuploidy, we cannot formally exclude that
insufficiency of this checkpoint protein has other cellular conse-
quences that may, in fact, be tumor promoting. Bub1 is not only
important for faithful chromosome segregation, but also is impli-
cated in triggeringapoptosis after abnormalmitoses (Jeganathan
et al., 2007). Bub1’s dual function in mitosis might diversify the
spectrum of chromosome losses and gains tolerated by primary
cells, thereby facilitating tumor suppressor gene LOHat the initial
stages of cell transformation. MEFs with low amounts of Bub1
respond normally to a broad spectrum of DNA damaging agents
(Jeganathan et al., 2007), indicating that pathways that mediate
DNA repair or apoptosis following DNA damage are not depen-
dent on Bub1. In addition, these MEFs showed no evidence of
increased structural chromosome damage, including chromo-
some translocations and fusions, large insertions and deletions,
and single and double strand breaks (Jeganathan et al., 2007),
further arguing against a role for Bub1 outside of mitosis.
Bub1 Loss and Tumorigenesis: Impact of Cellular
and Genetic Context
Although our work reported here demonstrates that Bub1
insufficiency can drive tumorigenesis by eliminating tumor484 Cancer Cell 16, 475–486, December 8, 2009 ª2009 Elsevier Inc.suppressor genes through loss of whole chromosomes, it also
reveals that it does so only in the context of select tumor
suppressor genes and specific tissues. For instance, in the
context of Pten haploinsufficiency, Bub1 loss acts to inhibit the
initiation of neoplastic growth in prostate epithelial cells, presum-
ably by increasing apoptosis and reducing cell proliferation in
early-stage neoplastic cells. It is tempting to speculate that
high aneuploidy rates in prostate epithelial cells underlie both
these cellular effects. We find that Pten is different from p53,
Apc, and Rb in that loss of a single Pten allele causes relatively
high percentages of aneuploidy in splenocytes. Pten is further
unique in that loss of one Pten allele in combination with Bub1
insufficiency leads to unusually high rates of chromosome mis-
segregation in splenocytes. It has been proposed that extensive
gene copy number variation associated with aneuploidy leads to
major imbalances in the stoichiometry of protein complex
subunits, thereby increasing proteotoxic stress and limiting repli-
cative potential (Luo et al., 2009; Papp et al., 2003; Torres et al.,
2007; Torres et al., 2008). However, it should be stressed that,
because of the experimental restrictions, it was not possible to
assess whether the aneuploidy rates observed in splenocytes
also apply to prostate epithelial cells. Furthermore, it cannot be
excluded that Bub1 insufficiency inhibits formation of PIN lesions
in a cell nonautonomous fashion, for instance by altering the
tumor microenvironment. Finally, it is important to note that the
inhibitory effects of Bub1 insufficiency are restricted to the early
stages of prostate tumorigenesis. This is consistent with the idea
that aneuploidy creates a selective pressure for mutations that
allow cells to neutralize the adverse effects of chromosome
imbalances on cell growth and survival (Holland and Cleveland,
2009; Torres et al., 2008). Experimental limitations for detecting
near diploid aneuploidies in prostate lesions precluded us from
determining whether such adaptation leads to tumors with
increased chromosomal instability. Whether Bub1 insufficiency
promotes advanced stage prostate tumorigenesis remains
unknown, because the number of mice in our study was too
small to detect potential differences in the number of PIN IV
lesions between Pten+/– and Bub1–/H/Pten+/– males.
Even though Bub1 insufficiency significantly increased the
rate of chromosome missegregation in Rb heterozygous mice,
it had no effect on pituitary tumorigenesis. There are several
possible explanations for this result. First, Bub1 hypomorphism
may have little negative impact on the accuracy of chromosome
missegregation in the pituitary. Again, because of technical limi-
tations, we were unable to exclude this possibility. However,
chromosome counts on various kinds of cultured primary cells
from wild-type and Bub1–/H mice indicated that increased aneu-
ploidy is a global rather than a cell-type specific consequence
of Bub1 insufficiency in somatic cells (Figure S1). Importantly,
of all Bub1–/H cell types tested, only male germ cells showed
no increase in aneuploidy (Table 1). Second, Bub1 insufficiency
may accelerateRb LOH through loss of chromosome 14 carrying
the residual wild-type Rb allele, but this chromosome might
harbor one or more genes whose dosage is critical for cell
viability. Third, Rb heterozygous mice may undergo efficient
LOH through a mechanism other than whole chromosome insta-
bility, such as mitotic recombination. However, involvement of
chromosomal instability cannot be fully excluded. For instance,
we find that Rb insufficiency induces low, yet significant
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aberrant expression of E2F target genes with mitotic functions
(Bracken et al., 2004). Furthermore, Rb has also been shown
to prevent chromosome missegregation through its role in regu-
lating pericentric heterochromatin structure and function (Isaac
et al., 2006).
A striking finding was that colonic tumor formation in ApcMin/+
mice was dramatically increased when Bub1 was insufficient,
whereas tumorigenesis in the adjacent small intestine was
unaffected. This might reflect potential differences in chromo-
somal instability between the two tissues. However, it is also
possible that aneuploidy rates are the same but that the resulting
mitotic and proteotoxic stress phenotypes are different in
epithelial cells of small and large intestine tissues. For instance,
chromosomal instability in colon may have no impact on cell
proliferation, whereas in the small intestine it may result in
delayed cell-cycle progression, senescence and/or apoptosis.
The earlier finding that haploinsufficiency of the Bub1-related
gene BubR1 in ApcMin/+ mice suppresses polyp formation in
the small intestine while promoting tumorigenesis in the large
intestine (Rao et al., 2005) supports the idea that the cellular
response to aneuploidy resulting from mitotic checkpoint failure
is distinct in both tissues.
EXPERIMENTAL PROCEDURES
Mouse Strains
Bub1–/H mice (Jeganathan et al., 2007) were bred to p53–/– (Jacks et al., 1994)
to generate Bub1+/H/p53+/– and Bub1+/–/p53+/– mice. These mice were then
intercrossed to generate p53+/–, Bub1+/H/p53+/–, Bub1+/–/p53+/–, Bub1H/H/
p53+/–, and Bub1–/H/p53+/– mice. Bub1+/H, Bub1+/–, Bub1H/H, and Bub1–/H
cohorts were as described elsewhere (Jeganathan et al., 2007). Bub1–/H
mice were crossed to Rb+/– mice (Jacks et al., 1992) and the resulting
Bub1+/H/Rb+/– and Bub1+/–/Rb+/– mice were interbred to establish Bub1–/H/
Rb+/–, Bub1–/H, and Rb+/– experimental cohorts. A similar breeding strategy
was used to generate Bub1–/H/Pten+/–, Bub1–/H, and Pten+/– mice. Both
Rb+/– and Pten+/– (Podsypanina et al., 1999) mutant mice were acquired
from theMouseModels of HumanCancers Consortium, at theNational Cancer
Institute. All the above mice were on a C57BL/6 3 129/Sv mixed genetic
background. Bub1–/H mice on a C57BL/6 3 129/Sv mixed genetic back-
ground were first backcrossed to C57BL/6 mice for ten generations and
then to ApcMin/+ C57BL/6 inbred mice (Moser et al., 1990; Jackson Labora-
tory). The resulting Bub1+/H/ApcMin/+ and Bub1+/–/ApcMin/+ mice were inter-
bred to generate Bub1+/H/ApcMin/+, Bub1–/H/ApcMin/+, Bub1+/–/ApcMin/+,
Bub1+/–, Bub1–/H, and ApcMin/+ experimental cohorts. Animals were housed
in a pathogen-free environment for the duration of the study and monitored
daily for tumor formation or ill health. All mouse experiments were conducted
after approval of the Mayo Clinic Committee on Animal Care and Use. Prism
software (GraphPad Software) was used for the generation of survival curves
and statistical analysis.
Tumor Analysis in p53 and Rb Mutant Mice
Moribund animals were sacrificed and subjected to a complete necropsy.
Questionable areaswere removed and processed for routine histopathological
analysis. Board-certified pathologists assisted in the characterization of tumor
samples. A Fisher’s exact test was used to compare the incidence of tumors
between the various genotypes. For p53 LOH analysis, genomic DNA was ex-
tracted from thymic lymphoma and sarcoma samples and analyzed by
Southern blotting or PCR as described elsewhere (Jacks et al., 1994). For
Rb LOH analysis, fresh tumor samples weremicrodissected, and DNAwas ex-
tracted. PCR analysis was performed as described elsewhere (Keramaris
et al., 2008). Lysates of pituitary tumors and normal flanking brain tissue
were prepared for Western blotting as described elsewhere (Jeganathan
et al., 2007). Antibodies used were as follows: rabbit anti-human Bub1C(25-165) (Jeganathan et al., 2007), rabbit anti-human BubR1, and mouse
anti-alpha tubulin (Sigma, T-9026).
Analysis of Intestinal Tumors
Analysis of intestinal tumors was performed as described elsewhere (Rao
et al., 2005). For LOH analysis, fresh tumor samples were isolated and sub-
jected to a previously reported PCR-based method for detection of Apc+
and ApcMin (Luongo et al., 1994).
Prostatic Intraepithelial Neoplasia Analysis
At 6 months of age, five Bub1–/H/Pten+/– and five Pten+/– mice were sacrificed
by CO2 asphyxiation. Whole prostates were collected, fixed in 10% formalin,
and processed for histological evaluation according to standard methods.
Five-micrometer paraffin sections were prepared of the entire prostate. One
of every 10 sections was stained with hematoxylin and eosin and screened
for PIN II, III, and IV lesions using light microscopy. Our classification of PIN
lesions was based on previously published criteria (Park et al., 2002). Pyknotic
nuclei were determined as described elsewhere (Wang et al., 1998). Immuno-
histochemistry for PCNA (Zymed, 93-1143) and Pten (Millipore, 04-035) were
performed according to instructions provided by the manufacturers. In vivo
BrdU labeling experiments were performed as described elsewhere (Baker
et al., 2008).
Karyotype, FISH, SSLP, and SCE Analyses
Metaphase spreads of mouse splenocytes were prepared and analyzed for
numerical and structural chromosome abnormalities as described elsewhere
(Jeganathan et al., 2007). Chromosome counts on cultured primary cells
from various nonhematopoietic mouse tissues are described in the Supple-
mental Data. Spectral karyotypic analysis was performed using the protocol,
reagents, instrumentation and software from Applied Spectral Imaging.
SSLP and FISH analysis for chromosomes 4, 7, 9, 11, 12, and 18 and SSLP
were as described in the Supplemental Data. SCE analysis on MEFs was
performed as described elsewhere (German and Alhadeff, 2001).
SUPPLEMENTAL DATA
Supplemental data include five figures and Supplemental Experimental Proce-
dures and can be found with this article online at http://www.cell.com/
cancer-cell/supplemental/S1535-6108(09)00387-0.
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